Safety of meloxicam: A global analysis of clinical trials

British Journal of Rheumatology

Volumn 35, Issue SUPPL. 1, 1996, Pages 68-77

  Distel, M ^a,c   Mueller, C ^a   Bluhmki, E ^a   Fries, J ^b  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Boehringer Ingelheim   (Argentina)

Author keywords

Cyclooxygenase; Gastrointestinal; Meloxicam; NSAID; PUB; Safety

Indexed keywords

DICLOFENAC; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN SYNTHASE;

ABDOMINAL PAIN; ARTICLE; CLINICAL TRIAL; DRUG SAFETY; DYSPEPSIA; ENZYME INHIBITION; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; META ANALYSIS; NEPHROTOXICITY; NEUROTOXICITY; OSTEOARTHRITIS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SKIN DISEASE; ULCER PERFORATION; URINARY TRACT DISEASE;

EID: 0029979358     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/35.suppl_1.68     Document Type: Article

References (23)

1. Giercksky KE, Huseby G, Rugstad HE. Epidemiology of NSAID-related gastrointestinal side effects. Scand J Gastroenterol 1989;24(163):3-8.
2. Fries J. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991;18(suppl. 28):6-10.
3. Langman MJS, Weil J, Wainwright P et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075-8.
4. Garcia-Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
5. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787-96.
6. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971;231:232-5.
7. Masferrer JL, Seibert K, Zweifel B, Needleman P. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA 1992;89:3917-21.
8. Vane JR. Towards a better aspirin. Nature 1994;367:215-6.
9. Engelhardt G. Meloxicam a potent inhibitor of COX-2. Data presented at the 9th International Conference on Prostaglandins and Related Compounds, Florence, Italy, 1994, p. 82.
10. Churchill L, Graham A. Farina P, Grob P. Inhibition of human cyclooxygenase-2 (COX-2) by meloxicam. Rheumatol Eur 1995;24(suppl. 3):272.
11. Pairet M, Engelhardt G. The preferential inhibition of COX-2 by meloxicam is highly dependent on the structure of the drug. Rheumatol Eur 1995;24(suppl. 3):272.
12. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler Chr. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995;44:423-33.
13. Cooperating Clinics Committee of the American Rheumatism Association. A seven-day variability trial of 499 patients with peripheral rheumatoid arthritis. Arthritis Rheum 1965;8:302-34.
14. Arnett FC, Edworthy SM, Block DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
15. World Health Organization. Adverse reaction terminology list. Uppsala, WHO, 1990.
16. Kalbfleisch JD, Prentice RL (eds). The statistical analysis of future time data. New York: Wiley, 1980.
17. Larkai EN, Smith JL, Lidsky MD, Sessoms SL, Graham DY. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol 1989;11:158-62.
18. Bateman N. NSAIDs: time to re-evaluate gut toxicity. Lancet 1994;343:1051-2.
19. Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA. Identification of patients at risk for gastropathy associated with NSAID use. J Rheumatol 1990;17:12-9.
20. Murray MD, Brater C. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Ann Rev Pharmacol Toxicol 1993;32:435-65.
21. Anon. Relative safety of oral non-aspirin NSAIDs. Curr Problems Pharmacol 1994;20:9-12.
22. Mitchell JA, Akarasereenont P, Thiemerman Chr, Flower R, Vane JR. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994;90:11693-7.
23. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-4.